However, as far as we know, this study shows for the first time that c-Myc, through the activation of the mevalonate pathway, sustains mutp53 expression level in pancreatic cancer cells, giving back to this oncosuppressor—becoming an oncogene—the favor to be transactivated by it. Here, MYC is linked to pancreatic neoplasm.